{
  "success": true,
  "pagesUsed": [
    0,
    1,
    2,
    3,
    4,
    5,
    6,
    10,
    11,
    23,
    28,
    30,
    38,
    41,
    44,
    47,
    48,
    49,
    51,
    53
  ],
  "modelUsed": "gemini-3-flash-preview",
  "confidence": 1.0,
  "documentStructure": {
    "documentContentReferences": [
      {
        "id": "ref_1",
        "name": "Home Infusion Appendix Reference",
        "instanceType": "DocumentContentReference",
        "sectionNumber": "10.10",
        "sectionTitle": "Appendix J",
        "description": "Reference for country-specific home infusion requirements and inclusion/exclusion criteria"
      },
      {
        "id": "ref_2",
        "name": "Clinical Laboratory Evaluations Reference",
        "instanceType": "DocumentContentReference",
        "sectionNumber": "10.1",
        "sectionTitle": "Appendix A",
        "description": "Reference for the complete list of laboratory analytes"
      },
      {
        "id": "ref_3",
        "name": "Concomitant Medication Reference",
        "instanceType": "DocumentContentReference",
        "sectionNumber": "6.2.6",
        "sectionTitle": "Concomitant Medications",
        "description": "Reference for excluded and allowed concomitant medications"
      },
      {
        "id": "ref_4",
        "name": "Vaccination Schedule Japan",
        "instanceType": "DocumentContentReference",
        "sectionNumber": "10.9",
        "sectionTitle": "Appendix I",
        "description": "Reference for the specific vaccination schedule for patients in Japan"
      },
      {
        "id": "ref_5",
        "name": "Study Schedule of Events",
        "instanceType": "DocumentContentReference",
        "sectionNumber": "6.1",
        "sectionTitle": "Table 3",
        "description": "Reference to the primary schedule of events table"
      },
      {
        "id": "ref_6",
        "name": "Quality of Life Appendices",
        "instanceType": "DocumentContentReference",
        "sectionNumber": "10.3-10.8",
        "sectionTitle": "Appendices C through H",
        "description": "References to various QOL assessment scales (FACIT-Fatigue, EQ-5D-5L, SF-12, PGIC, PGIS, Healthcare Resource Utilization)"
      }
    ],
    "commentAnnotations": [
      {
        "id": "annot_1",
        "text": "The name and numbering of the protocol is based on a new numbering system followed by the Sponsor.",
        "annotationType": "Note",
        "instanceType": "CommentAnnotation",
        "sourceSection": "Document History",
        "pageNumber": 2
      },
      {
        "id": "annot_2",
        "text": "Any patient withdrawing from the study after Week 5 and prior to the Week 23 visit will be considered a non-responder.",
        "annotationType": "Note",
        "instanceType": "CommentAnnotation",
        "sourceSection": "Responder definition",
        "pageNumber": 31
      },
      {
        "id": "annot_3",
        "text": "BIVV009 doses of 6.5 grams (if <75 kg) or 7.5 grams (if ≥75 kg) based on patient’s baseline body weight will be administered via IV infusion",
        "annotationType": "Footnote",
        "instanceType": "CommentAnnotation",
        "sourceSection": "Table 3 - Study schedule of events (Footnote i)",
        "pageNumber": 45
      },
      {
        "id": "annot_4",
        "text": "In patients who consented to the use of their blood samples for future research, PD back-up samples collected at the following time points Day 7, 35, 77, 133 and 175, may be used to assay ADA.",
        "annotationType": "Clarification",
        "instanceType": "CommentAnnotation",
        "sourceSection": "Weeks 1-25",
        "pageNumber": 50
      }
    ],
    "studyDefinitionDocumentVersions": [
      {
        "id": "ver_1",
        "versionNumber": "06",
        "status": "Approved",
        "instanceType": "StudyDefinitionDocumentVersion",
        "versionDate": "2019-12-19",
        "description": "Amended Clinical Trial Protocol 06 - Global",
        "amendmentNumber": "Amendment 6"
      },
      {
        "id": "ver_2",
        "versionNumber": "5.0",
        "status": "Final",
        "instanceType": "StudyDefinitionDocumentVersion",
        "versionDate": "2018-07-17",
        "description": "Clinical Study Protocol Version 5 - Global",
        "amendmentNumber": "Amendment 5"
      },
      {
        "id": "ver_3",
        "versionNumber": "4.0",
        "status": "Final",
        "instanceType": "StudyDefinitionDocumentVersion",
        "versionDate": "2018-06-29",
        "description": "Clinical Study Protocol Version 4 - Global",
        "amendmentNumber": "Amendment 4"
      },
      {
        "id": "ver_4",
        "versionNumber": "1.0",
        "status": "Final",
        "instanceType": "StudyDefinitionDocumentVersion",
        "versionDate": "2017-08-24",
        "description": "Clinical Study Protocol - Global",
        "amendmentNumber": "Original"
      }
    ],
    "summary": {
      "referenceCount": 6,
      "annotationCount": 4,
      "versionCount": 4
    }
  }
}